In a report issued on May 4, Jason Kolbert from Dawson James maintained a Buy rating on Cytosorbents (CTSO – Research Report), with a price target of $16.00. The company's shares closed last Friday at $1.86, close to its 52-week low of $1.80. According to TipRanks.com, Kolbert 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.0% and a 33.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Cytosorbents has an analyst consensus of Strong Buy, with a price target consensus of $9.00, a 359.2% upside from current levels.
https://www.tipranks.com/news/blurbs/dawson-james-thinks-cytosorbents-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral